Fig. 2From: Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccineInfectivity of the GAP vaccine. Parasitemia was monitored by collecting blood samples and performing qPCR targeting the gene encoding P. falciparum 18S rRNA. Arrows indicate the commencement of treatment with artemether/lumefantrine for subjects who developed parasitemia. Time points at which parasitemia could not be detected were substituted with a value of 1 parasite/mL for the purpose of graphing on a logarithmic scale. Subject 7 was confirmed to be positive for influenza B at the time of antimalarial treatmentBack to article page